{"id":"NCT00539305","sponsor":"University of Washington","briefTitle":"Hormone and Information Processing Study","officialTitle":"Testosterone Supplementation in Men With MCI","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-07","primaryCompletion":"2011-07","completion":"2012-05","firstPosted":"2007-10-04","resultsPosted":"2014-07-14","lastUpdate":"2014-07-14"},"enrollment":22,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Mild Cognitive Impairment","Alzheimer's Disease"],"interventions":[{"type":"DRUG","name":"testosterone gel","otherNames":["Solvay Testosterone Gel"]},{"type":"DRUG","name":"placebo gel","otherNames":[]}],"arms":[{"label":"Study drug; testosterone transdermal gel","type":"EXPERIMENTAL"},{"label":"2","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to examine the effects of testosterone (T) replacement on changes in thinking and memory, as well as mood in older men with mild cognitive impairment (MCI) and low T levels. The study will also examine whether taking testosterone has effects on biological markers related to Alzheimer's disease.","primaryOutcome":{"measure":"Behavioral & Mood Measure: Profile of Mood States (POMS)","timeFrame":"Baseline, 3 and 6 months","effectByArm":[{"arm":"Treatment Group","deltaMin":57.7,"sd":2.2},{"arm":"Placebo Group","deltaMin":55.5,"sd":2}],"pValues":[]},"eligibility":{"minAge":"60 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":9,"exclusionCount":16},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["11445632","15668427","15985573","17145137","16344336"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":10},"commonTop":["PSA elevated above 4.0 ng/ml","Emergency room with chest pains"]}}